Compare AIZ & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIZ | IONS |
|---|---|---|
| Founded | 1892 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 11.9B |
| IPO Year | N/A | 1996 |
| Metric | AIZ | IONS |
|---|---|---|
| Price | $216.09 | $75.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 23 |
| Target Price | ★ $258.17 | $87.30 |
| AVG Volume (30 Days) | 277.2K | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.42 | N/A |
| Revenue Next Year | $5.48 | $64.88 |
| P/E Ratio | $12.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $174.97 | $23.95 |
| 52 Week High | $246.31 | $86.74 |
| Indicator | AIZ | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 51.25 |
| Support Level | $207.65 | $69.05 |
| Resistance Level | $223.08 | $75.60 |
| Average True Range (ATR) | 4.51 | 2.28 |
| MACD | 0.51 | 0.63 |
| Stochastic Oscillator | 39.68 | 84.37 |
Assurant Inc is a protection company that partners with the brands to safeguard and service connected devices, homes and automobiles. It operate in North America, Latin America, Europe and Asia Pacific through two operating segments: Global Lifestyle and Global Housing. Global Lifestyle: includes mobile device solutions (including extended service contracts, insurance policies and related services), extended service contracts and related services for consumer electronics and appliances, and financial services and other insurance products. Global Housing: includes lender-placed homeowners, manufactured housing and flood insurance, as well as voluntary manufactured housing, condominium and homeowners insurance. Key revenue is generated from Global Lifestyle segment.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).